| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6031007 | DENTSPLY PHARM | Pharmaceutical composition with anaesthetic effect |
Apr, 2017
(7 years ago) | |
Oraqix is owned by Dentsply Pharm.
Oraqix contains Lidocaine; Prilocaine.
Oraqix has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Oraqix are:
- US6031007
Oraqix was authorised for market use on 19 December, 2003.
Oraqix is available in gel;periodontal dosage forms.
Oraqix can be used as management of pain and discomfort associated with peridontal scaling and root planning procedures by application of an eutectic mixture of local anesthetics to peridontal pockets.
The generics of Oraqix are possible to be released after 01 April, 2017.
Drugs and Companies using LIDOCAINE; PRILOCAINE ingredient
Market Authorisation Date: 19 December, 2003
Treatment: Management of pain and discomfort associated with peridontal scaling and root planning procedures by application of an eutectic mixture of local anesthetics to peridontal pockets
Dosage: GEL;PERIODONTAL
ORAQIX family patents
